

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
華康生物醫學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8622)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 13 JANUARY 2020**

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”) and the circular of the Company dated 23 December 2019 (the “**Circular**”). Unless otherwise specified herein, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING (THE “EGM”)

The Board is pleased to announce that the proposed resolution (the “**Resolution**”) as set out in the EGM Notice was duly passed by the Shareholders by way of poll at the EGM held on 13 January 2020.

The poll results in respect of the Resolution proposed at the EGM is as follows:

Ordinary Resolution	Number of votes (%) (Approximate percentage)	
	For	Against
To approve and adopt the Share Option Scheme (as defined in the Circular).	300,000,000 (100%)	0 (0%)

Notes:

- (a) As all of the votes were cast in favour of the resolution, the resolution was duly passed as ordinary resolutions.
- (b) As at the date of the EGM, the total number of shares of the Company in issue was 400,000,000 shares.

- (c) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the EGM was 400,000,000 shares.
- (d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 17.47A of the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).
- (e) No shareholder of the Company was required under the GEM Listing Rules to abstain from voting on the resolutions at the EGM.
- (f) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.
- (g) The Company’s branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

For and on behalf of
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 13 January 2020

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Mr. Kwok Chi Shing and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.